Sudarshan Pharma Surges to 52-Week High on Fundraising Plan, Faces Profit Booking Amid Market Rally

Sudarshan Pharma Surges to 52-Week High on Fundraising Plan, Faces Profit Booking Amid Market Rally​

Sudarshan Pharma shares touched a fresh 52-week high after the company announced plans for raising funds through equity and debt instruments. The stock saw sustained upward momentum as it rose from its previous close in line with the broader market rally. This surge was driven by the announcement of the proposed fundraising initiative.

Stock Reaches All-Time Peak Amid Fundraising Announcement​

The pharmaceutical firm's scrip closed near its peak after achieving a strong intraday high. Sudarshan Pharma opened at ₹37.50 on the BSE, marking an increase of ₹0.33 or 0.88 percent from its previous closing price of ₹37.17. The stock later climbed to an intraday high of ₹38, setting a new record for the company.

The stock had been in a four-session ascent prior to this session. Although the initial sentiment was strongly positive due to the funding news, profit booking emerged during the trading day, causing the stock to trade lower subsequently. The company's 52-week low is recorded at ₹18.50, which it hit on January 29, 2026.

Board Meeting Scheduled for Capital Raising Approval​

The increased investor interest is linked to a proposed corporate action concerning future funding. Sudarshan Pharma stated that its Board of Directors meeting has been scheduled for June 18, 2026. The purpose of this crucial meeting is to consider and approve the proposal for raising funds through various methods.

The company said it would review instruments such as private placement, preferential issue, warrants, or debt instruments. This capital-raising effort is subject to necessary statutory and regulatory approvals.

Equity Share Allotment Details Revealed​

Beyond the proposed fundraising meeting, the company disclosed details regarding its warrant committee decisions. The committee approved the allotment of 90 lakh equity shares intended for individuals categorized as promoters. These equity shares hold a face value of Re 1 each. The allotments have been finalized at an issue price of ₹16.983 per share.